1022961-12-1

Basic information

• Product Name: 2-amino-3-chloro-5-fluorobenzoic acid
• Synonyms: 2-amino-3-chloro-5-fluorobenzoic acid
• CAS NO: 1022961-12-1
• Molecular Formula: C₇H₅ClFNO₂
• Molecular Weight: 189.5715032
• Mol File: 1022961-12-1.mol

Chemical Properties

• Boiling Point: 315.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.574±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.23±0.10(Predicted)
• CAS DataBase Reference: 2-amino-3-chloro-5-fluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-3-chloro-5-fluorobenzoic acid(1022961-12-1)
• EPA Substance Registry System: 2-amino-3-chloro-5-fluorobenzoic acid(1022961-12-1)

Safety Data

• Hazardous Substances Data: 1022961-12-1(Hazardous Substances Data)

Upstream product

• 446-08-2 2-amino-5-fluorobenzoic acid 

Relevant articles and documents

Synthetic method of A2A adenosine receptor antagonist

The invention discloses a synthesis method of an A2A adenosine receptor antagonist, which comprises the following steps: by using 2-amino-5-fluorobenzoic acid as an initial raw material, carrying outan electrophilic substitution reaction with N-chlorosuccinimide to obtain an intermediate 1; carrying out a condensation acylation reaction on the intermediate 1 and urea to obtain an intermediate 2;carrying out cyclization on the intermediate 2 and phosphorus oxychloride to obtain an intermediate 3; subjecting the intermediate 3 and 2-furanboric acid to a coupling reaction to obtain an intermediate 4; protecting the intermediate 4 by a p-methoxybenzyl protecting group to obtain an intermediate 5; subjecting the intermediate 5 to a hydroxylation reaction to obtain an intermediate 6; subjecting the intermediate 6 and 4-(2-chloroethyl)-morpholine to a nucleophilic substitution reaction to obtain an intermediate 7; and removing the p-methoxybenzyl protecting group from the intermediate 7 toobtain the A2A adenosine receptor antagonist. The whole synthesis route is reasonable and mature, raw materials are easy to obtain, reaction conditions are mild, controllability is high, the method issuitable for industrial production, and the yield and purity of a target product are guaranteed.

FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF

Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3Kδ, and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.

Synthesis of insecticidal fluorinated anthranilic diamides

A series of highly active fluorinated anthranilic diamide insecticides have been prepared and their biological activity assessed on two aphid species in the search for systemically active compounds that control Hemiptera. In addition, we have demonstrated a new synthesis of N-aryl 3-fluoropyrazoles.